Jean Marie Poirier

Summary

Country: France

Publications

  1. ncbi request reprint Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-
    Jean Marie Poirier
    Department of Pharmacology, Saint Antoine University Hospital, 27 rue Chaligny, 77571 Paris Cedex 12, France
    Ther Drug Monit 24:302-9. 2002
  2. ncbi request reprint Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
    Jean Marie Poirier
    Department of Pharmacology, Saint Antoine University Hospital, 27 rue Chaligny, 75571 Paris Cedex 12 France
    Ther Drug Monit 27:186-92. 2005
  3. doi request reprint Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection
    Jean Marie Poirier
    Service de Pharmacologie, Universite Paris VI, Faculte de Medecine Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, France
    J Chromatogr B Analyt Technol Biomed Life Sci 867:277-81. 2008
  4. doi request reprint Sustained increase of HDL cholesterol over a 72-week period in HIV-infected patients exposed to an antiretroviral regimen including lopinavir/ritonavir
    Jean Luc Meynard
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Paris, France
    J Int Assoc Physicians AIDS Care (Chic) 7:311-6. 2008
  5. ncbi request reprint Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C
    Laurent Becquemont
    Department of Pharmacology and the Clinical Investigation Center, Saint Antoine University Hospital, Paris, France
    Clin Pharmacol Ther 71:488-95. 2002
  6. doi request reprint Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C
    Jean Luc Meynard
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Hopital Saint Antoine, Paris, France
    J Antimicrob Chemother 63:579-84. 2009
  7. ncbi request reprint Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors
    Jean Marie Poirier
    AIDS 20:1087-9. 2006
  8. ncbi request reprint Atazanavir urinary stones in an HIV-infected patient
    Jerome Pacanowski
    AIDS 20:2131. 2006
  9. ncbi request reprint Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir
    Jean Baptiste Guiard-Schmid
    AIDS 19:1937-8. 2005
  10. ncbi request reprint Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir
    Jean Baptiste Guiard-Schmid
    J Acquir Immune Defic Syndr 41:393-4; author reply 394. 2006

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-
    Jean Marie Poirier
    Department of Pharmacology, Saint Antoine University Hospital, 27 rue Chaligny, 77571 Paris Cedex 12, France
    Ther Drug Monit 24:302-9. 2002
    ....
  2. ncbi request reprint Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
    Jean Marie Poirier
    Department of Pharmacology, Saint Antoine University Hospital, 27 rue Chaligny, 75571 Paris Cedex 12 France
    Ther Drug Monit 27:186-92. 2005
    ..This assay was developed for the purpose of therapeutic monitoring (TDM) in HIV-infected patients...
  3. doi request reprint Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection
    Jean Marie Poirier
    Service de Pharmacologie, Universite Paris VI, Faculte de Medecine Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, France
    J Chromatogr B Analyt Technol Biomed Life Sci 867:277-81. 2008
    ..The described assay was developed for the purpose of therapeutic drug of this HIV integrase inhibitor...
  4. doi request reprint Sustained increase of HDL cholesterol over a 72-week period in HIV-infected patients exposed to an antiretroviral regimen including lopinavir/ritonavir
    Jean Luc Meynard
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Paris, France
    J Int Assoc Physicians AIDS Care (Chic) 7:311-6. 2008
    ..This increase was positively correlated with the exposure to lopinavir/ritonavir during the first 24 weeks...
  5. ncbi request reprint Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C
    Laurent Becquemont
    Department of Pharmacology and the Clinical Investigation Center, Saint Antoine University Hospital, Paris, France
    Clin Pharmacol Ther 71:488-95. 2002
    ..Interferon alpha (IFN-alpha) is thought to be responsible for cytochrome P450 (CYP)-dependent drug interactions mediated by a decrease in CYP activities...
  6. doi request reprint Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C
    Jean Luc Meynard
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Hopital Saint Antoine, Paris, France
    J Antimicrob Chemother 63:579-84. 2009
    ..However, data evaluating the impact of liver fibrosis stages on the plasma efavirenz level are lacking...
  7. ncbi request reprint Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors
    Jean Marie Poirier
    AIDS 20:1087-9. 2006
  8. ncbi request reprint Atazanavir urinary stones in an HIV-infected patient
    Jerome Pacanowski
    AIDS 20:2131. 2006
  9. ncbi request reprint Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir
    Jean Baptiste Guiard-Schmid
    AIDS 19:1937-8. 2005
  10. ncbi request reprint Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir
    Jean Baptiste Guiard-Schmid
    J Acquir Immune Defic Syndr 41:393-4; author reply 394. 2006
  11. pmc High variability of plasma drug concentrations in dual protease inhibitor regimens
    Jean Baptiste Guiard-Schmid
    Department of Clinical Infectious and Tropical Diseases, Tenon Hospital, Paris, France
    Antimicrob Agents Chemother 47:986-90. 2003
    ....